Mark B Carbeau insider trades: Interleukin Genetics (ILIU) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mark reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 29, 2016 | ILIU | ↑ Buy | 100,603 | $0.10 | $10K | Direct | Aug 1, 2016 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Mark B Carbeau's insider trades
Mark B Carbeau is CEO at Interleukin Genetics (ILIU). Since Jul 29, 2016, Mark has reported 1 open-market purchase worth $10K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (7 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ILIU insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.